GlaxoSmithKline (GSK) has agreed to divest its non-core European OTC brands to Omega Pharma for €470 M (US$614 M) in order to streamline its consumer healthcare business. The divested brands had combined sales of approximately £185 M (US$297 M) in 2011. Omega Pharma will also gain GSK’s manufacturing site at Herrenberg, Germany, where a number of the divested brands are manufactured. The deal will strengthen Omega Pharma’s presence in key markets including Germany, the UK, Poland and Italy.